Who founded Rayze Bio?

Rayze Bio was founded by Ken Song in 2020.

Who are Rayze Bio's investors?

Rayze Bio's investors include Samsara BioCapital, Scion Life Sciences, Sofinnova Ventures, TCG Crossover, venBio Partners, Versant Ventures, Vivo Capital, venBio Global Strategic.

How much funding has Rayze Bio raised?

Rayze Bio has disclosed $396.4M raised across 4 rounds.

Where is Rayze Bio headquartered?

Rayze Bio is headquartered in San Diego, US.

Rayze Bio

San Diego, US · Founded 2020 · Delaware corporation · 283 employees on LinkedIn · 8 known investors

Find your way into Rayze Bio

354 people in our graph share verified history with the Rayze Bio team — schools, employers, funds. One of them is your warm intro.

Wesley Chanunlockedknows Ken Song · together at Massachusetts Institute of Technology (overlapped)

×11knows the team · via Massachusetts Institute of Technology

RayzeBio develops radiopharmaceutical therapies for cancer treatment. The company is a subsidiary of Bristol Myers Squibb focused on advancing targeted cancer therapies to patients.

Biotech Healthtech Medical Devices

Founders & leadership

Rayze Bio was founded in 2020 by Ken Song.

Ken Song inFounderKen Song is co-founder and former president and CEO of RayzeBio, a radiopharmaceutical company he led from its 2020 founding through its acquisition by Bristol Myers Squibb in 2023 for $4.1 billion. He previously co-founded and led Ariosa Diagnostics through its commercialization and 2015 acquisition by Roche, and trained in internal medicine and gastroenterology at UCSF and University of Washington respectively.

Ben HickeyinPresident

Abhi Bhat, PhDSenior Vice President, Research & Development

Deborah CharychNamed on SEC filing

Yi LarsonNamed on SEC filing

Board

Aaron Royston in 𝕏Board of Directors2020–2023Managing Partner at venBio Partners

Jerel Davis in 𝕏Board Member2020–2023Managing Director at Versant Ventures

Bong KohBoard director

Aaron Kantoff inFounding Board Member2020–2024Managing Partner at Scion Life Sciences

Investors · 8

Samsara BioCapitalPalo Alto

Scion Life SciencesNew York · $1K – $60M

Sofinnova VenturesMenlo Park · $100K – $15M

TCG CrossoverPalo Alto

venBio PartnersSan Franciscovia Aaron Royston · board

Versant VenturesSan Francisco · $250K – $5M

Vivo CapitalPalo Alto · $10M – $50M

venBio Global StrategicreportedSan Francisco

Reported raises · per SEC filings

Form D private placements

$396.4M disclosed across 4 rounds · 2020–2022

▶$167.9MraisedSep 2022 · 18 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Aaron KantoffDirector
Angie YouDirector
Aaron RoystonDirector
Yi LarsonDirector
Aubrey HaddachExecutive Officer
Mary TagliaferriDirector
Jerel DavisDirector
Ken SongExecutive Officer, Director
Arvind KushExecutive Officer
Maha KatabiDirector
Alex RosenDirector

Offering amount: $167.9M
Amount sold: $167.9M
First sale: Aug 2022
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$108.5MraisedJun 2021 · 23 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Deborah CharychExecutive Officer
Aaron RoystonDirector
Jerel DavisDirector
Ken SongExecutive Officer, Director
Bong KohDirector
Aaron KantoffDirector
Yi LarsonDirector

Offering amount: $108.5M
Amount sold: $108.5M
First sale: Jun 2021
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$105MraisedDec 2020 · 17 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Bong KohDirector
Ken SongExecutive Officer, Director
Aaron KantoffDirector
Jerel DavisDirector
Aaron RoystonDirector

Offering amount: $105M
Amount sold: $105M
First sale: Nov 2020
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$15MraisedNov 2020 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Aaron RoystonDirector
Jerel DavisDirector
Aaron KantoffDirector
Ken SongExecutive Officer, Director

Offering amount: $45M
Amount sold: $15M
First sale: Aug 2020
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

3 people who came through Rayze Bio went on to found or lead other companies.

Richard HeymanChairman of the BoardFounded Aragon Pharmaceuticals +2 Angie YouBoard MemberFounded Architect Therapeutics Ken SongExecutive Officer, DirectorFounded Candid Therapeutics

Competitors · 1

by search overlap

Bioworld23 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Rayze Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Rayze Bio do?: RayzeBio develops radiopharmaceutical therapies for cancer treatment. The company is a subsidiary of Bristol Myers Squibb focused on advancing targeted cancer therapies to patients.
Who founded Rayze Bio?: Rayze Bio was founded by Ken Song in 2020.
Who are Rayze Bio's investors?: Rayze Bio's investors include Samsara BioCapital, Scion Life Sciences, Sofinnova Ventures, TCG Crossover, venBio Partners, Versant Ventures, Vivo Capital, venBio Global Strategic.
How much funding has Rayze Bio raised?: Rayze Bio has disclosed $396.4M raised across 4 rounds.
Where is Rayze Bio headquartered?: Rayze Bio is headquartered in San Diego, US.